| Phase III Trial Finds Pfizer's Axitinib Better than Sorafenib at Boosting PFS ... - Genetic Engineering News |
|
|
Genetic Engineering News Pfizer reported positive data from a Phase III study comparing its VEGF receptor inhibitor axitinib with sorafenib therapy, in patients with advanced renal cell carcinoma whose disease had progressed after prior therapy with sunitinib (Pfizer's |